Targeting PTGI2/ANX2/TF pathways, such as treatment with cabpaprost, inhibits nuclear ANXA2 transport, controls monocyte TF activity, and prevents the occurrence of DVT (255). Here, ANXA2 is linked to deep vein thrombosis.